“Of course I’m not deceiving you,” Elizabeth Holmes asserted to Nathan Fielder in the promotional teaser that sparked countless internet reactions for his documentary exploring the Theranos founder's legacy. Throughout the 174-minute runtime, Holmes repeatedly maintains that she never misled the public regarding her disgraced blood-testing enterprise.

Following the film's strong box office performance and subsequent Academy Award speculation, whistleblower Tyler Schultz—whose pivotal testimony helped secure Holmes' criminal conviction for fraud—argued that she cleverly manipulated Fielder during a segment discussing Theranos technology. Schultz criticized the documentary for skating close to creating unwarranted public skepticism about whether Holmes actually engaged in deception.

The 2015 Forbes Healthcare Summit Clash

This pattern of evasion is hardly unprecedented. Former editorial staffer Matthew Herper detailed in 2018 that the foundation of Theranos rested entirely on cascading falsehoods. Herper spoke from direct experience, having conducted a high-stakes fireside chat with Holmes at the Forbes Healthcare Summit in December 2015. This encounter occurred directly after pioneering exposés by Wall Street Journal journalist John Carreyrou brought the startup's alleged fraudulent activities to light.

During the session, Holmes cultivated the persona of an underdog enterprise besieged by entrenched corporate rivals. Herper later characterized the conversation akin to athletic sparring, noting that her ability to deflect questions surpassed anyone he had ever interviewed.

Definitive Claims of Profitability

Yet, a single exchange remains particularly striking due to its absolute finality. When discussing the diagnostic blood evaluations her firm claimed to execute independently, Holmes made a bold declaration:

We’ve now, in Arizona, done over 4.1 million tests. We’ve billed at 50 to 80% off of Medicare, and people come to us because we’re redefining that model.

When Herper directly questioned whether those evaluations yielded a profit margin at such deep discounts, Holmes offered a categorical response:

They are.

Financial reality, however, painted an entirely different picture. Court testimony from former corporate finance controller Danise Yam alongside official 2015 tax documentation revealed that Theranos bled tens of millions annually since its inception in 2003. By the close of 2015—the very year Holmes boasted of commercial success—the firm had accumulated a staggering $585 million deficit, generating a meager $429,000 in revenue against a net loss of roughly $111 million.

Legal Fallout and Current Status

Despite these dismal economic fundamentals, Holmes routinely pitched wildly inflated financial projections to financial backers, projecting a fictitious $112 million in revenue for that fiscal year alone. These calculated deceptions directed at investors ultimately resulted in a federal jury convicting Holmes on three counts of wire fraud and one count of conspiracy, landing her an 11-year prison sentence.

Having completed three years behind bars, Holmes is currently scheduled for an early transition to a residential reentry facility next summer. Furthermore, she has petitioned the presidential administration for a full commutation of her remaining sentence, a legal appeal that remains pending.